Skip to content

Validation Study of a Peri-intervention Diabetes Management Algorithm (DIAPI) for Endoscopy Procedures

Validation Study of a Peri-intervention Diabetes Management Algorithm (DIAPI) for Endoscopy Procedures

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05849714
Enrollment
173
Registered
2023-05-09
Start date
2023-09-01
Completion date
2024-12-01
Last updated
2025-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Peri-procedural, Endoscopy

Brief summary

The peri-endoscopy management of diabetes mellitus creates significant challenges for both patients and healthcare professionals. These procedures require fasting and in certain situations, such as prior to a colonoscopy, the diet must be modified the day before the intervention and patients need to take a laxative. These factors put patients at high risk for hyperglycemia and hypoglycemia. Inadequate diabetes control or the continuation of certain medications during this period can be dangerous for the patient and lead to the cancellation of the procedure. DIAPI is a web application designed to generate orders for optimal and personalized treatment based on each patient's antidiabetic treatment, their glycemic control, their risk of hypoglycemia, and the intervention-related variables. DIAPI's algorithm is established on current evidence-based data when available, and experts' opinions. Information generated by DIAPI: * For the patient: Clear instructions regarding their diabetes medication management for the days preceding and the day of the endoscopy. * For the health care team: * Clear instructions regarding patient's diabetes medication management for the days preceding and the day of the endoscopy; * Individualized hyperglycemia protocol; * Hypoglycemia protocol; * Guidelines if SGLT2 inhibitors have not been discontinued pre-intervention; * Suggestion on whether an Endocrinology consultation is needed. DIAPI aims to simplify the complex task of peri-intervention diabetes management while ensuring patient safety. It is a cost-effective solution that can lead to a reduction of unnecessary Endocrinology consultations, a decrease in nurses' workload, a lessening of the risk of errors and a diminution of endoscopy cancellation. The validation study is divided into two main phases. * Phase 1 - Concordance. The investigators will assess the reproducibility of DIAPI orders when two different healthcare workers (an endocrinologist and a nurse) collect data for the same patient. The investigators hypothesize that DIAPI orders are concordant in 80%. Patients in this phase will be subjected to the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's. This group will be the control arm for the non-inferiority study (Phase 2). * Phase 2 - Non-inferiority study. The investigators hypothesize that DIAPI's orders are not inferior to the recommendations issued by the treating-physician in terms of efficacy and security. Patients in this phase will be subjected DIAPI's orders. This group will be the intervention arm for the non-inferiority study.

Interventions

OTHERPeri-intervention Diabetes Management Algorithm (DIAPI)

Patients and healthcare workers will apply DIAPI's orders.

OTHERUsual Care

Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Living with diabetes mellitus for at least 6 months * Receiving pharmacological treatment for diabetes mellitus * Awaiting an endoscopy intervention scheduled in 2 weeks or more in order to have time to prepare for the study participation

Exclusion criteria

* Undergoing an urgent endoscopy intervention * Being pregnant * Currently treated with an insulin pump or the insulin Entuzity

Design outcomes

Primary

MeasureTime frameDescription
Concordance rate of duplicate prescriptions generated by DIAPI when two different healthcare workers collect data for the same patient. (Part 1 of study)1 weekConcordance and discordance are dichotomic concepts. To classify this binary issue, the investigators use a home-made ''Difference Score''. The components of this score have been established to ensure patient safety by minimizing the risk of hypoglycemia, hyperglycemia, and diabetic ketoacidosis. * Concordance = difference score of ≤ 25.0 %. * Discordant= difference score of \> 25.0 %.
proportion of patients with glycaemia level within target from arrival to departure from the endoscopy unit, i.e. between 4 - 10 mmol/L. (Part 2 of study)1 dayThe glycaemia will be measured at least every hour for the duration of the stay in the endoscopy unit.

Secondary

MeasureTime frameDescription
Healthcare workers' satisfaction level with the use of DIAPI, assessed by a questionnaire. (Part 1 of study)1 week
Proportion of participants who followed DIAPI recommendations. (Part 2 of study)1 week
Proportion of DIAPI orders for which the endocrinologist disagrees with at least one of its recommendations. (Part 1 of study)1 week
Proportion of participants hospitalized for a diabetes-related condition. (Part 2 of study)1 month
Proportion of participants who experienced: episode of hypoglycemia <3 and < 4 mmol/L, episode of hyperglycemia >10, > 15 and >20 mmol/L, episode of ketoacidosis. (Part 2 of study)1 weekThese episodes will be reported by time frame: the day before, the same day and the day after the intervention.
• Proportion of canceled endoscopies due to dysglycemia, ketoacidosis or for reasons related to diabetes management. (Part 2 of study)1 week
Proportion of participants for whom an endocrinology consultation was recommended by DIAPI. (Part 1 of study)1 week

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026